Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Amgen in
the ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark Amgen' s performance against key rivals in the ethical
pharmaceutical sector
- See how Amgen will suffer as a consequence of recent safety warnings
concerning Aranesp and Epogen restricting their sales growth
- Evaluate the impact Phase III musculoskeletal product denosumab will have
on the company' s growth
View Cart
